LONHALA® MAGNAIR® (glycopyrrolate) Savings Programs

LONHALA MAGNAIR Savings Programs

Co-pay can be as little as $20 for commercially insured patients*

Once you have prescribed LONHALA MAGNAIR through the completed enrollment form to Sunovion Answers (SA) Plus for LONHALA MAGNAIR, specialists from SA Plus for LONHALA MAGNAIR will perform a benefits investigation and apply a co-pay savings if the patient is eligible.

Free trial vouchers* for LONHALA MAGNAIR are available, please reach out to SA Plus for LONHALA MAGNAIR for details.

*Restrictions may apply, Please see LONHALA MAGNAIR Terms & Conditions.

Learn about SA Plus for LONHALA MAGNAIR's services, including built-in benefits investigations and prior authorization assistance.

View Details 

Terms and Conditions

By using this program, you acknowledge that you currently meet the following eligibility requirements:
You must be 18 years of age or older to accept this offer. This offer is valid only for eligible patients and legal guardians of eligible patients. Patients must have a valid prescription for LONHALA MAGNAIR within LONHALA MAGNAIR’s approved indication. Offer not valid if prescription is paid in part or full by any state or federally funded health care program, including but not limited to Medicare, Medicaid, VA, DoD or TRICARE, or where prohibited by law.

This program is valid for up to $500 off each prescription fill for up to a 30-day supply. The program is further limited to twelve (12) qualifying prescription fills. Offer is limited to one per person and may not be used with any other offer. This program is not health insurance. The amount of the benefit cannot exceed the patient’s out-of-pocket expenses.

Acceptance of this offer must be consistent with the terms of any drug benefit provided by a health insurer, health plan, or other third-party payer. If requested or required by any such payer, the patient must report the use of this program. The patient must deduct the value of the savings received under this program from any reimbursement request submitted to the patient’s insurance plan, either directly or on the patient’s behalf.

For California and Massachusetts residents, benefits pursuant to this program will terminate automatically upon the introduction of a therapeutically equivalent product. Offer valid only in the United States and Puerto Rico. Void where prohibited by law, taxed or restricted. Sunovion reserves the right to rescind, revoke or amend this offer at any time without notice. This offer is not transferable and may not be sold, purchased or traded, or offered for sale, purchase or trade.

To the Patient: You must present this card, if applicable, to the pharmacist along with your prescription to participate in this program. If you have any questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the LONHALA MAGNAIR Savings Program at 1-844-276-8262 anytime between 8:00AM—8:00PM (EST). By using this program, you are certifying that you understand the enclosed program rules, regulations, and terms and conditions; you have not submitted and will not submit a claim for reimbursement under any federal, state or other governmental program for this prescription or where otherwise prohibited by law in your state; and you will otherwise comply with the terms mentioned herein.

To the Pharmacist: When you use this program, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state or other governmental program for this prescription. If benefit does not apply automatically, submit transaction to McKesson Corporation using BIN #610524. If primary commercial prescription insurance exists, input program information as secondary coverage and transmit using the COB segment of the NCPDP transaction. Applicable discounts will be displayed in the transaction response. Acceptance of this program and your submission of claims for the program are subject to the LoyaltyScript® program Terms and Conditions posted at www.mckesson.com/mprstnc. Patient is not eligible if prescriptions are paid in part or full by any state or federally funded health care program, including but not limited to Medicare or Medicaid, VA, DoD or TRICARE, or where prohibited by law. For questions regarding setup, claim transmission, patient eligibility or other issues, call the LoyaltyScript® Savings Card program at 1-844-276-8262, from 8:00AM—8:00PM (EST), Monday through Friday.

Free Trial Offer Terms and Conditions

To use this voucher, you must meet the following eligibility requirements: You must be 18 years of age or older to accept this offer. This offer is valid only for eligible patients and legal guardians of eligible patients. Patients must have a valid prescription for LONHALA® MAGNAIR® (glycopyrrolate) Inhalation Solution within LONHALA MAGNAIR's approved indication. This voucher is valid for a 30-day free trial of LONHALA MAGNAIR. Limit one voucher per patient per year. No purchase necessary. Refills are not required.  This voucher is not transferable. No substitutions are permitted. This offer cannot be combined with any other free trial, coupon, discount, prescription savings card, or other offer. This voucher is not health insurance. Claim shall not be submitted to any public or private third-party payer or any federal or state health care program for reimbursement. Offer valid only in the United States and Puerto Rico. Void where prohibited by law, taxed, or restricted. It is illegal to sell, purchase, trade, counterfeit, or offer to sell this voucher. Void if reproduced. Sunovion reserves the right to rescind, revoke, or amend this offer at any time without notice.  

Important Safety Information & Indication

Important Safety Information
 

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

Indication
 

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.